Practical Asymmetric Synthesis of Efavirenz (DMP 266), an HIV-1 Reverse Transcriptase Inhibitor
作者:Michael E. Pierce、Rodney L. Parsons、Lilian A. Radesca、Young S. Lo、Stuart Silverman、James R. Moore、Qamrul Islam、Anusuya Choudhury、Joseph M. D. Fortunak、Dieu Nguyen、Chi Luo、Susan J. Morgan、Wayne P. Davis、Pat N. Confalone、Cheng-yi Chen、Richard D. Tillyer、Lisa Frey、Lushi Tan、Feng Xu、Dalian Zhao、Andrew S. Thompson、Edward G. Corley、Edward J. J. Grabowski、Robert Reamer、Paul J. Reider
DOI:10.1021/jo981170l
日期:1998.11.1
A highly enantioselective and practical synthesis of the HIV-1 reverse transcriptase inhibitor efavirenz (1) is described. The synthesis proceeds in 62% overall yield in seven steps from 4-chloroaniline (6) to give efavirenz (1) in excellent chemical and optical purity. A novel, enantioselective addition of Li-cyclopropyl acetylide (4a) top-methoxybenzyl-protected ketoaniline 3a mediated by (1R,2S)-N-pyrrolidinylnorephedrine lithium alkoxide (5a) establishes the stereogenic center in the target with a remarkable level of stereocontrol.